BRIDGEBIO PHARMA, INC. (BBIO)

Director Valantine Hannah 🟡 adjusted position in 8.7K shares (1 derivative) of BridgeBio Pharma, Inc. (BBIO) at $72.00 ($1.1M) Transaction Date: Mar 10, 2026 | Filing ID: 000260